Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.
Also called NCT01147666
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 161 participants
- Registry
-
NCT01147666
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01147666. Randomized; double masking; primary purpose treatment. Start 2010-05-17 (actual); primary completion 2012-10-15 (actual). Results posted on 2022-01-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis
- Condition
- End Stage Renal Disease
- Condition
- Anemia
- Intervention (Drug)
- Roxadustat
- Intervention (Drug)
- Epoetin Alfa
- Intervention (Other)
- Placebo
- Lead sponsor
- Kyntra Bio
- Collaborator
- AstraZeneca
- Collaborator
- Astellas Pharma Inc
Record details
- Record id
cardio:ct-nct01147666- Content hash
f6ba3a5ed85b4ee20d08b3ba078438dfd59d60c6349ebfa1da3b16da5b44d9dd